-
Innovation Ranking
NewInnovation Ranking – Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Inc (Pieris) is a clinical-stage biotechnology company that carries out the discovery and development of anticalin-based drugs. The company’s pipeline product includes inhaled IL-4Rα antagonist Anticalin protein. It offers drug candidates such as PRS-060/AZD1402, PRS-220, PRS-440, PRS-342 and PRS-352, among others. Pieris also carries out AstraZenca programs and Genetech programs against respiratory diseases. The company offers therapeutics for the treatment of respiratory diseases, oncology and other diseases. It leverages Anticalin technology platform to develop and advance its pipeline...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp Alfa in Gastric Cancer Drug Details: PRS-343 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dostarlimab in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dostarlimab in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dostarlimab in Peritoneal Cancer Drug Details: Dostarlimab (Jemperli) is a immunoglobulin...
-
Product Insights
Vulvar Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vulvar Cancer - Drugs In Development, 2023’, provides an overview of the Vulvar Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Rectal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Rectal Cancer - Drugs In Development, 2023’, provides an overview of the Rectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Esophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophageal Squamous Cell Carcinoma (ESCC) - Drugs In Development, 2023’, provides an overview of the Esophageal Squamous Cell Carcinoma (ESCC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Squamous Cell Carcinoma (ESCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...